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SUMMARY 
There are four types of xenograft rejection. They are referred to as hyperacute rejection, acute 
humoral xenograft rejection, acute cellular xenograft rejection and chronic rejection. 
Hyperacute rejection is mediated by natural xenoreactive antibodies (mainly directed against 
the antigen α-Gal found on porcine cells) that activates the classical complement pathway. 
Acute cellular xenograft rejection is mediated by xenoreactive IgM and IgG, that seems to 
damage the xenograft by among other things activating complement and endothelial cells. 
Acute cellular xenograft rejection is mediated by T cells and NK cells that act cytotoxic on 
the endothelium. Chronic rejection results in four different types of vasculopathy, which lead 
to occlusion of arteries, and in vascular fibrosis. Although a lot of research has been 
conducted in recent years, for example transgenic swines that does not express α-Gal have 
been generated, more remains to be done before xenotransplantation can be conducted 
clinically.  
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SAMMANFATTNING 
Det finns idag fyra mekanismer beskrivna för avstötning av xenotransplantat. Dessa är 
hyperakut avstötning, akut humoral xenotransplantat avstötning, akut cellulär 
xenotransplantat avstötning och kronisk avstötning. Hyperakut avstötning medieras av 
naturliga xenoreaktiva antikroppar, vilka främst är riktade mot antigenet α-Gal på svinceller 
och aktiverar komplement systemet (den klassiska vägen). Akut humoral xenotransplantat 
avstötning medieras också av xenoreaktiva IgM och IgG, som verkar skada xenotransplantatet 
bland annat genom aktivering av komplementsystemet och endotelceller. Akut cellulär 
xenotransplantat avstötning medieras av T-celler och NK-celler, som verkar cytotoxiskt på 
endotelet. Kronisk avstötning ger upphov till fyra typer av vaskulopati, vilket leder till 
förträngning av artärer, och till fibros av kärl. Trots att framsteg har gjorts inom forskningen, 
tillexempel har transgena grisar som inte uttrycker α-Gal framställts, måste mer göras innan 
xenotransplantation kan komma till klinisk användning.  
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INTRODUCTION 
Experiments with organ transplantation have been carried out since the beginning of the 20
th
 
century (Starzl, 2000). Since the first successful human transplantation was conducted in 1954 
between two identical twins organ transplantations have been used as treatment for end-stage 
diseases. Due to the lack of available organs, the possibility of xenotransplantation, i.e. the 
transplantation of organs between different species, has been studied (Gonzalez-Stawinski et 
al., 2002). Xenografts are rejected by the recipient’s immune system in a sequence of 
rejection mechanisms (Gonzalez-Stawinski, 2002), that all are an obstacle to the clinical use 
of xenotransplantation. 
 
The aim of this essay is to summarize the mechanisms for immunological xenograft rejection 
known today and which parts of the immune system that are involved in these. 
 
My intent is to describe the immune reactions by which xenografts transplanted from animals 
(mainly swine) to humans are rejected. There are however more difficulties in using xeno-
transplantation clinically than rejection by the immune system. These include microbiological 
(transfer of microorganisms and infectious agents from the donor to the recipient) and 
physiological differences between humans and other species (Cooper, 2003). Because of lack 
of space these will only briefly be discussed here. Neither is it not within the scope of this 
essay to discuss immune suppression drugs and other methods used to prevent immune 
rejection. I only mention generation of transgenic pigs lacking the α-Gal epitope because of its 
great importance. 
 
Concept explanations and abbreviations 
Xenotransplantation Transplantation of organs between different species. 
 
Xenograft A graft that is transplanted between different species. 
 
Heterotopic transplantation Transplantation of an organ to another site than its natural 
anatomical position. 
 
HAR Hyperacute rejection 
 
AHXR Acute humoral xenograft rejection 
 
ACXR Acute cellular xenograft rejection 
 
Delayed xenograft rejection Delayed xenograft rejection (DXR), also called acute vascular 
xenograft rejection (McCurry et al., 1997), is a generally 
acknowledged notion for acute rejection of xenografts, but 
there exists disagreement as to how the notion is used. Chen et 
al. (2004) mean that DXR is rejection mediated by both 
antibodies and cells. However Hisashi et al. (1998) divide  
acute rejection into two parts. These authors propose that DXR 
only is an antibody-mediated rejection (in their article DXR is 
also synonymous with acute humoral xenograft rejection), 
while the cellular rejection is referred to as acute cellular 
xenograft rejection. To avoid confusion in this essay the acute 
antibody-mediated rejection will be designated “acute humoral 
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xenograft rejection” and for the acute cellular rejection “acute 
cellular xenograft rejection” will be used, despite that DXR 
might have been used in the articles referred to. 
 
α-Gal Short for galactose-α(1,3)-galactose. It is a carbohydrate 
epitope found on porcine cells (but not cells from human, apes 
and Old World monkeys). It is the main antigen that the 
antibodies, which cause hyperacute rejection, bind to (Chen et 
al., 1999) and is also involved in acute humoral xenograft 
rejection (McCurry et al., 1997). 
 
GalT-KO swine Short for α1,3-galactosyltransferase gene-knockout swine. 
They are transgenic pigs that lack the enzyme 1,3-
galactosyltrans-ferase, which generates α-Gal.  
 
Xenoreactive antibodies Antibodies that is directed against epitopes on a xenograft. 
  
Natural antibodies  Antibodies that an individual possesses without prior 
immunisation against the antigen. The individual however 
might have been immunised by crossreaction from bacterial 
epitopes. 
 
MATERIALS AND METHODS  
Articles were searched on the Internet using three different databases. These were PubMed, 
Science Direct and Web of Knowledge. On PubMed “mechanism of hyperacute xenograft 
rejection” gave 58 results. On Science Direct it gave 17 results. On Web of Knowledge it 
gave 219 results. “Mechanism of delayed xenograft rejection” gave 26 results on PubMed, on 
Science Direct 25 and 105 on Web of Knowledge. ”History of clinical transplantation” gave 
3310 results on PubMed. Searching for ”α-Gal AND xenograft” on PubMed gave 140 results. 
Articles containing experiments with transplantations of organs from pigs to baboons were 
preferred.  
 
LITERATURE REVIEW 
 
Immunological rejection of xenografts 
Xenografts are rejected by the recipient’s immune system by four different rejection 
mechanisms (Hisashi et al., 2008). These are referred to as hyperacute rejection, acute 
humoral xenograft rejection, acute cellular xenograft rejection and chronic rejection. They are 
mentioned below in the chronological order that they are responsible for the rejection of a 
xenograft. If the graft is rejected within 48 hours after transplantation the rejection is 
hyperacute. If the graft is rejected up to 7 days post-transplantation the rejection is 
denominated acute. Chronic rejection occurs months after transplantation. Xenograft rejection 
is often defined as the loss of function of the organ, for example the termination of beating of 
a heart (McCurry et al., 1997; Chen et al., 2000). 
 
Hyperacute rejection 
Chen et al. (1999) found that heterotopic xenotransplantation of hearts from pigs to baboons 
resulted in hyperacute rejection (HAR) 30-60 minutes post transplantation. If HAR occurs 
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after transplantation the species are termed discordant, whereas if HAR does not transpire the 
species are said to be concordant (McCurry et al., 1997).  
 
HAR is seen histologically as diffuse interstitial oedema and focal haemorrhage with thrombi 
(consisting of fibrin and thrombocytes) in the smaller blood vessels (Dalmasso et al., 1992). 
Such lesions were observed in cardiac and renal xenografts from pigs transplanted to rhesus 
monkeys. Furthermore components of the complement system (C3, C4, C5 and C9 with the 
membrane attack complex, MAC) and IgM were found on the endothelial surface of the 
xenograft’s blood vessels. The authors could not find depositions of factor B and only small 
amounts of factor P, also components of the complement system. The complement system 
consists of three distinct cascade reactions, three “pathways”. Complement proteins cleave 
each other in the cascade reactions. The three pathways end in the same terminal pathway, to 
which C5, C3 and C9 belong. The terminal pathway ends with polymerisation of C9, that 
together with C5b, C6, C7 and C8 form MAC. MAC inserts in the cell membrane of a foreign 
cell, forms a pore and the cell dies by osmotic lysis. C4 is together with subunits of C1 the 
major constituent of the classical pathway, which is activated by IgM and IgG. Factor B and P 
participate in the alternative pathway that is activated by spontaneous breakdown of C3. 
According to Dalmasso et al (1992) their findings indicate that complement caused damage to 
xenografts during HAR is generated by the classical pathway. Further studies done in vitro by 
the same authors, investigating human serum toxicity on porcine endothelial cells, came to the 
same conclusion. Serum deficient in components of the classical pathway did not trigger an 
immune response, but when lacking components of the alternative pathway a response was 
observed (Dalmasso et al., 1992). 
 
 
Figure 1. The depositions found on xenogeneic blood vessels rejected by HAR. Modified from 
Dalmasso et al. (1992).  
 
In the study mentioned above (Dalmasso et al., 1992) removal of antibodies from the blood of 
the monkeys prevented the deposition of complement components and antibodies in the 
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xenografts’s blood vessels a few hours post-transplantation. Furthermore human serum 
lacking IgM was not cytotoxic on porcine endothelial cells in vitro.  
 
HAR of porcine xenografts transplanted to Old World monkeys is mainly caused by the 
binding of natural antibodies from the recipient to carbohydrate structures on the endothelial 
surface of blood vessels of the xenografts (Chen et al., 1999). The principal carbohydrate 
epitope is named galactose-α(1,3)-galactose (α-Gal) (Chen et al., 1999). Most mammals 
(including swines) possess it, only excluding humans, apes and Old World monkeys. Chen et 
al. (1999) found that α-Gal epitopes were expressed in a higher amount in small blood vessels 
than larger. In consistence with this, IgM and MAC were found in a higher quantity in small 
vessels. Lack of α-Gal on porcine cells leads to reduced cell lysis by complement (Baumann 
et al., 2004). 
 
Also subclasses of IgG can provoke HAR (Ding et al., 2008). In accordance with Chen et al. 
(1999) these are directed against α-Gal. Hearts from rats, expressing α-Gal, were transplanted 
into the abdomens of mice that did not express α-Gal. Injection of these mice with anti-Gal 
IgG provoked HAR and the grafts were rejected after 5-7 days. 
 
In an attempt to preclude HAR, consistent with the finding of Baumann et al. (2004), 
production of α1,3-galactosyltransferase-deficient swines has been performed (Phelps et al., 
2003). α-1,3-galactosyltransferase is the enzyme that generates α-Gal. Phelps et al. (2003) 
accomplished production of α1,3-galactosyltransferase-deficient swine by somatic cell 
nuclear transfer (cloning). The production of pigs lacking α-Gal was considered a possible 
way to overcome the obstacle of HAR (Itescu et al., 1998). This is proved by Hisashi et al 
(2008) in an experiment where hearts from α1,3-galactosyltransferase gene-knockout (GalT-
KO) pigs were transplanted into baboons. No HAR was observed and one graft survived for 
nearly 6 months.  
 
Acute humoral xenograft rejection 
The α-Gal epitope is not only the key factor causing HAR (Chen et al., 1999), it also has a 
vital part in eliciting acute humoral xenograft rejection (AHXR) (McCurry et al., 1997). In 
cardiac xenografts from swine heterotopically transplanted into baboons 70-95% of the 
xenoreactive IgM and 85-95% of IgG were directed against α-Gal. The authors believe that 
antibodies directed against other antigens also contributed to the rejection. These antigens 
were integrins α1, αv, α3/ α5, β1 and β3 chains. Also Hisashi et al. (2008) demonstrated that 
other antigen than α-Gal mediate AHXR. In their study AHXR occurred in baboon recipients, 
whose porcine cardiac xenografts did not express α-Gal. 
  
Xenoreactive antibodies align alongside the xenogeneic vascular endothelium (McCurry et 
al., 1997). These authors thus conclude that when a graft is in situ the antibodies are within 
the graft and for that reason the amount in serum is small. After extraction of a graft 
antibodies can be detected in sera. Chen et al. (2004) observed the same result independent on 
the findings of McCurry et al. (1997), where the amount of xenoreactive antibodies in serum 
decreased after transplantation.  
 
Hisashi et al. (2008) transplanted hearts from GalT-KO swines into baboons. Their 
histological findings were numerous, including arterial fibrinoid necrosis. They also found 
microthrombi in the blood vessels (thrombotic microangiopathy) and neutrophils and foci of 
haemorrhage in the interstitium. Thrombosis occured in capillaries (in the cases where 
rejection was slow) and also in arteries (in the cases where rejection was swift). In the blood 
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vessels IgM, IgG, C3, C4d, and C5b-C9 were deposited. This is consistent with the finding of 
Chen et al. (2004), who found the same depositions in hearts transplanted from pigs to rhesus 
monkeys. Hisashi et al. (2008) report that the amount of complement components and 
antibodies increased when the quantity of microthrombi increased. The results of Chen et al. 
(2004) and Hisashi et al. (2008) have previously been demonstrated by Chen et al. (2000), 
who found IgM and MAC deposited along the small blood vessels of porcine cardiac 
xenografts heterotopically transplanted to baboons.   
 
 
Figure 2. Some of the histological findings and  depositions found in AHXR-rejected xenografts. 
Modified from Hisashi et al. (2008). 
McCurry et al. (1997) tested specificity differences of antibodies in serum taken before 
transplantation (preimmune sera) and after (immune sera). In most animals no difference in 
the binding of IgM was found. The authors conclude that the binding of natural IgM 
antibodies (which existed in both the preimmune sera and the immune sera) to foreign 
antigens on the transplant prevented antibodies formed during transplantation to bind. The 
specificity of IgG antibodies in the immune serum was however different from that of IgG in 
the preimmune sera. 
  
Xenoreactive antibodies may mediate AXHR in four different ways (McCurry et al., 1997): 
 
 Activation of the endothelium, which results in a change of function and structure of 
endothelial cells. For example it can lead to a rise in intracellular pH (which increases cell 
division) and a change in permeability of the cell membrane to molecules.  
 Activation of the complement system, which acts on the endothelium and leads to an 
increase in neutrophil adhesion to the endothelium.  
 Mediate the activity of Natural Killer cells (NK cells) and other cells with Fc-receptors. 
 Antibodies bind to essential endothelial molecules, such as integrins. In doing so the 
antibodies may disturb the molecules’ function, which for integrins comprises the control 
of diapedesis.   
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Porcine hearts survive up to 12 days before rejection by AHXR (McCurry et al., 1997). 12-24 
hours before rejection the graft gets bradychardia and lengthened QRS complexes on 
electrocardiography (Chen et al., 2000).  
 
Acute cellular xenograft rejection 
Acute cellular xenograft rejection (ACXR) is often masked by the more rapid AHXR (Hisashi 
et al., 2008). In absence of HAR, cardiac xenografts from infant piglets transplanted into baby 
baboons, survived for 83-96 hours (Itescu et al., 1998). Though some indications of HAR 
were detected the rejected grafts were mainly infiltrated by macrophages, NK cells and T 
cells. This finding corresponds with experiments where a porcine kidney ex vivo was 
perfused with human blood leukocytes (Khalfoun et al., 2000). Mainly T cells and NK cells 
were retained within the graft, because they bound to the endothelium of porcine renal 
capillaries. Their adherence led to endothelial damage in form of cell hypertrophy and 
changes in the basement membrane and podocytes. 
  
T cells alone can provoke xenograft rejection (Lin et al., 1999). CD4
+
 T cells (usually 
considered helper T cells, TH) or CD8
+
 T cells were injected into nude rats (which lack T cells 
of their own) after they had received a hamster heart xenograft. CD4
+
 T cells mediated 
production of IgG2a and IgG2b and a low quantity of IgG1 and IgG2c and IgM. Mononuclear 
cells infiltrated the graft. The CD4
+
 T cell-mediated rejection was histologically characterized 
by oedema in the interstitium, haemorrhage, necrosis in the myocardium and thrombi in the 
blood vessels. CD8
+
 T cells, considered cytotoxic T cells (CTLs), mediated rejection without 
production of xenoreactive antibodies. The grafts of these rats were infiltrated by 
mononuclear cells (some were CD8
+
) and the myocardium damaged. Lin et al. (1999) suggest 
that the rejection was mediated by CTLs that can “activate” themselves the absence of CD4+ 
helper T cells. CTLs kill foreign cells by two ways: the perforin pathway and the CD95 
pathway. In the perforin pathway the CTL secretes the proteins perforins and granzymes, 
which induces apoptosis of the foreign cell. In the other pathway binding of CD95L (CD178) 
to CD95 on the foreign cell also induces apoptosis.   
  
Human NK cells damage porcine endothelial cells by direct cell lysis and indirect lysis by 
antibody-dependent cell-mediated cytotoxcity (ADCC) (Baumann et al., 2004). In ADCC 
cells such as NK cells, monocytes and neutrophils bind to foreign cells via antibodies and kill 
the cells. The mechanism is not completely understood. NK cells kill foreign cells by 
inducing apoptosis both via the intrinsic pathway (by perforins, granulysin and NK lysin) and 
the extrinsic pathway (mediated via binding of CD95L to CD95). As proved by Baumann et 
al. (2004) direct NK cell lysis is independent on binding to α-Gal, whereas ADCC activity is 
reduced in the absence of α-Gal. Besides binding to antigens NK cell activity is influenced by 
antibodies and cytokines. Xenoreactive IgG antibodies evoke a weak NK cell lysis on porcine 
endothelial cells, whereas cytokines (such as interleukin-2) provoke a stronger response 
(Itescu et al., 1998). However Itescu et al. (1998) suggest that the response provoked by 
xenoreactive IgG antibodies are more significant biologically.  
 
Lin et al. (1999) further studied the influence of xenoreactive antibodies on ADCC mediated 
by unspecified cells. In their study naive nude rats were transplanted with hamster hearts and 
their complement system inhibited. They were then injected with serum containing 
xenoreactive IgG antibodies. Xenografts were rejected within 3.5 days (faster than for the 
control group). When the NK cells of the recipient were inhibited the grafts survived longer. 
The authors’ conclusion was that IgG xenoantibodies mediate xenograft rejection by 
activating complement and by causing ADCC.  
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In addition Hisashi et al. (2008) found infiltration of mainly polymorphonuclear cells, some 
mononuclear cells and macrophages in lately rejected porcine cardiac xenografts (from GT-
KO swine transplanted into baboons). The mononuclear cells however seemed not to have 
damaged the myocardium. In the more swiftly rejected grafts, in consistence with the studies 
mentioned above, mononuclear cells were identified. These were macrophages, B cells, CD4
+
 
T cells, CTLs and some NK cells.  The authors suggest that both ACXR and AHXR might be 
mediated by T cells and thus be T cell-dependent.  
 
The advances within xenotransplantation research that has found modes to overcome HAR 
opens up for ACXR to be the next obstacle to defeat (Hisashi et al., 2008). 
 
Chronic rejection and vasculopathy 
Chronic xenograft rejection occurs 78-179 days post-transplantation (Hisashi et al., 2008). In 
the xenograft endothelialitis, a thicker arterial intima and arterial fibrinoid necrosis develop. 
The arteries occlude due to thickening of smooth muscle cells. Smaller arteries are worse 
afflicted. Hisashi et al. (2008) identified four types of chronic xenograft vasculopathy, 
presented in Table 1. They suggest that fully developed vasculopathy is the result of chronic 
humoral and chronic cellular rejection-associated vasculopathy, since fibrosis was usually 
preceded in the arteries by infiltration of cells and deposition of fibrins. The mechanisms by 
which chronic rejection and vasculopathy are mediated is at present not completely 
understood. However Hisashi et al. (2008) argue that both cellular and humoral responses are 
involved and that chronic humoral rejection is the dominant one.   
  
Table 1. The four types of vasculopathy identified by Hisashi et al. (2008).  
Type of vasculopathy  Appearance 
Chronic humoral rejection-
associated vasculopathy 
  Thickening of the intima of arteries 
 TUNEL+ cells 
 Deposition of fibrin, IgM, IgG, C3,C4d and C5b-C9)   
Chronic cellular rejection-
associated vasculopathy 
  Presence of T cells, CTLs, macrophages and B-cells in 
the intima 
 Endothelialitis 
 TUNEL+ cells 
Combination of  chronic humoral 
and cellular rejection-associated 
vasculopathy 
  Fibrinoid deposition 
 Infiltration of antibodies, complement, T cells, 
macrophages and polymorphnuclear leukocytes in the 
intima 
Fully developed vasculopathy   Fibrosis in the intima 
 No cellular infiltration or fibrinoid material present 
 
 
DISCUSSION 
The pathogenesis of HAR seems to be elucidated. Since depositions of C3, C4, C5 and C9 
with MAC were found along the blood vessels of xenografts (Dalmasso et al., 1992) the 
simple conclusion is that natural xenoreactive antibodies activate the classical complement 
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pathway, resulting in MAC formation and osmotic lysis of xenogeneic cells. The finding that 
removal of antibodies in the blood abolished the rejection Dalmasso et al. (1992) further 
proves that antibodies initiate HAR. In HAR the main target of the antibodies or cells is the 
xenogeneic vascular endothelium (Dalmasso et al., 1992). This also seem to be the case for 
AXCR (Khalfoun et al., 2000), AHXR and chronic rejection (Hisashi et al., 2008). 
  
The pathogenesis of AHXR is probably similar to that of HAR, because the depositions of 
antibodies and complement factors found in blood vessels of AHXR rejected xenografts 
(Chen et al., 2004; Hisashi et al., 2008) were similar to those found in HAR rejected 
xenografts (Hisashi et al., 2008). It is very probable that the vascular damage is mediated by 
the depositions since Hisashi et al. (2008) found that the amount of microthrombi was most 
extensive at the site of most dense deposition. The occurrence of thrombi in the xenograft’s 
blood vessels as well as haemorrhage in the interstitium are other similarities between HAR 
and AHXR (Hisashi et al., 2008), which also indicate that their pathogenesises are alike.  
 
The reason that McCurry et al. (1997) failed to find a broadened specificity for IgM 
antibodies in immune sera compared to the preimmune sera can be due to low sensitivity of 
the method. The authors suggest that the natural IgM antibodies blocked the antigen binding 
sites for any IgM with a new specificity, for example by steric hindrance. The antigen binding 
sites for any IgM with a new specificity (in the immune sera) would then have to be close to 
the binding sites for natural IgM. Then the natural IgM (which are large molecules) could 
then physically block the epitopes recognized by an IgM with a new specificity.  
 
ACXR is mainly mediated by NK cells (Itescu et al., 1998; Khalfoun et al., 2000), CD4
+
 and 
CD8
+
 T cells (Lin et al., 1999). The histological image of CD4
+
 T cell mediated ACXR (Lin 
et al., 1999) is similar to that of HAR (Dalmasso et al., 1992) and AHXR (Hisashi et al., 
2008) (interstitial haemorrhage and vascular thrombosis) with myocardial necrosis as the new 
feature (Lin et al., 1999). However immune cells mediate the pathogenesis. The CD4
+
 T cells 
are presumably at least partly TH-2 cells, since production of subclasses of IgG and a little IgM 
was observed (Lin et al., 1999). These subclasses are likely produced by host B cells situated 
in the graft (also found in tissue by Hisashi et al. (2008)) after co-stimulation from TH-2 cells. 
Lin et al. (1999) showed that CTLs could activate themselves in the absence of TH-1 co-
stimulation and mediate rejection. However in the mammalian body TH-1 are commonly 
present. For that reason in the living body CTLs may not have the need to activate themselves 
when there are TH-1 cells present that can activate them. For that reason some of the CD4
+
 T 
cells can also be TH-1 cells. Removal of NK cells from the recipient’s blood resulted in longer 
graft survival (Lin et al., 1999), indicating that NK cells participate in ADCC-caused 
xenograft damage. 
 
There is no consensus regarding the main celltypes that are infiltrating the xenograft. Hisashi 
et al. (2008) found polymorphonuclear cells (the mononuclear cells they found did not seem 
to damage the myocytes), while Khalfoun et al. (2000) and Itescu et al. (1998) found mainly T 
cells and NK cells (both mononuclear cells). The scientists used different techniques for their 
experiments. Itescu et al. (1998) used infant baboons and newborn piglets. Khalfoun et al. 
(2000) used human cells (not baboons’ as the other two) on porcine kidneys, while Hisashi et 
al. (2008) used cardiac xenografts from GalT-KO swines transplanted to baboons. Newborn 
baboons have a different immune system (where all parts are not developed yet) than adult 
baboons. Their reaction to a xenograft for that reason probably differs. Human cells are 
possibly not identical to those of baboons. Perhaps α-Gal has a role in influencing the cell 
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type, since the results of Hisashi et al. (2008), that used organs from GalT-KO, differed from 
the other two.  
 
A key factor in all the reactions, except chronic rejection, is α-Gal. It is the major antigen 
involved in HAR (Chen et al., 1999), but it is also involved in AHXR (McCurry et al., 1997). 
However unlike HAR (which is prevented in the absence of α- Gal (Itescu et al., 1998)), 
AHXR still occurs (Hisashi et al., 2008). I have not found any article describing the 
histological image of α- Gal-mediated AHXR, so I cannot compare if α- Gal-dependent and 
α- Gal-independent AHXR differ. Also ACXR is influenced by α- Gal, since the absence of 
α- Gal reduces ADCC (Baumann et al., 2004).  
 
I have found only little information about chronic xenograft rejection, probably because the 
mechanism is not completely understood (Hisashi et al., 2008). In chronological order it is the 
final rejection mechanism, perhaps making it a low priority to research (the other rejections, 
except HAR, (Itescu et al.,1998) are still obstacles that needs to be overcome). Chronic 
xenograft rejection perhaps is similar to chronic allograft rejection. Allotransplantation is 
transplantation of an organ between individuals of the same species. Allograft vasculopathy is 
characterized by occlusion of the arteries due to smooth muscle cell proliferation, which leads 
to ischemic damage of the graft. The result of the ischemic damage is graft fibrosis 
(influenced by interleukin-13, transforming growth factor-β and fibroblast growth factor), a 
reaction called chronic allograft rejection. Also chronic xenograft rejection shows arterial 
occlusion with thickening of smooth muscle cells (Hisashi et al., 2008), but no graft fibrosis. 
Yet allograft and xenograft chronic rejection might be mediated by similar immune reactions.  
The lack of xenograft fibrosis might be due to extraction of the graft before long lasting 
damage (ie. to which fibrosis is a normal consequence) occurs. 
 
Although I have divided xenograft rejection into different parts according to Hisashi et al. 
(2008) it is important to realize that in reality the mechanisms may co-operate. For example 
both HAR (Chen et al., 1999) and AHXR (McCurry et al., 1997) are caused by xenoreactive 
antibodies. The difference between these reactions according to definition is that HAR is only 
caused by natural antibodies (Chen et al., 1999), whereas AHXR also can be mediated by 
antibodies formed post-transplantation (McCurry et al., 1997). In reality the borderline 
between the two reactions are thin. How are we to know if only natural antibodies or both 
natural antibodies and antibodies formed post-transplantation contribute to xenograft 
rejection?  
 
Ethical considerations are another obstacle to clinical xenotransplantation. Since they are not 
immunological aspects they will only briefly be discussed here. Xenotransplantation is an 
advantage for the human recipient, who is saved from dying of end-stage diseases (Cooper et 
al., 2000). Religious opposition can be due to considering that humans should protect all 
animals (Buddhism). However Judaism and Islam may accept xenotransplantation as a way of 
saving lives (Cooper et al., 2000). Some people deem xenotransplantation unacceptable, 
meaning that it disobeys the laws of nature. Another anxiety is the well-being of the pigs 
used. They are likely going to be bred separately from other pigs (though they probably will 
live in groups) in isolated areas (preventing them from being infected by infectious agents) 
(Cooper et al., 2000).  
 
I do not intend to judge the ethical aspects, only clarifying them. In the end it will be up to 
every candidate for xenotransplantation to decide if he or she wishes to live with a porcine 
organ. If xenotransplantation becomes a reality it is possible that religious leaders around the 
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world will decide their religion’s standpoint. For that reason it is now hard to know how 
different religions will react to xenotransplantation. The well-being of the pigs will probably 
be regulated by laws, but these may be different in different countries. This is how it is now 
for the laboratory animals. Precisely as for the situation of laboratory animals I do not think it 
is an issue that can be solved easily. Another ethical point I can see regarding the initial stages 
of clinical transplantations is the uncertainty of how long the graft will function. Even if 
researchers demonstrate long survival in baboons, we do not know for sure that a graft will 
function similarly in humans. The conclusion is that even if we can start transplanting we will 
not know the extent of success and the extent of survival until perhaps twenty years into the 
future (depending on the age of the recipients). That raises another ethical issue, if one graft 
fails after ten years, is it then okay to transplant another? How many pigs can be used per 
human?    
 
Another obstacle to xenotransplantation is the risk of transfer of microbiological agents, 
especially porcine endogenous retroviruses and exogenous viruses such as cytomegalovirus, 
from pigs to humans (Cooper, 2003). One step to prevent transfer of cytomegalovirus is to 
isolate and wean newborn piglets from their infected parents at an early age. Although not 
studied this method may also be used to prevent infections from other viruses. One risk I see 
is the risk for undetected viruses. I hardly believe that mankind has as of now detected all 
porcine viruses (especially those viruses that do not cause disease in the pigs themselves). For 
that reason we cannot prevent the donor pigs from being infected if we do not know of the 
existence of the viruses. A further threat is the ability of viruses to mutate. Even if the porcine 
virus itself does not cause disease in humans it may combine with a human virus. This 
mutated virus may be virulent and pose a threat to the health of not only the recipient but to 
other humans that the recipient is in contact with.  
 
In conclusion, although major research about xenotransplantation has been conducted in 
recent years and progress has been made, a lot of research remains to be conducted before the 
dream of clinical xenotransplantation as treatment for end-stage diseases can be realised. 
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